Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1148-1155

  Perin, T ^a   Canzonieri, V ^a   Massarut, S ^a   Bidoli, E ^a   Rossi, C ^a   Roncadin, M ^a   Carbone, A ^a  

^a NONE

Author keywords

c erbB 2; cath D; CD44; ductal carcinoma in situ of the breast; ER; MLuC5; p53; PR; pS2

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN D; ESTROGEN RECEPTOR; HERMES ANTIGEN; LAMININ RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MEDICAL DECISION MAKING; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030176129     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00037-8     Document Type: Article

References (32)

1. 1. Swain SM. Ductal carcinoma in situ. Cancer Invest 1992, 10, 443-454.
2. 2. Peeters PHM, Verbtek ALM, Straatman H, et al. Evaluation of overdiagnosis of breast cancer in screening with mammography. Int J Epidemiol 1989, 18, 295-299.
3. 3. van Dongen JA, Holland R, Peterse JL, et al. Ductal carcinoma in-situ of the breast; second EORTC Consensus Meeting. Eur J Cancer 1992, 28, 626-629.
4. 4. Patchefsky AS, Schwanz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989, 63, 731-741.
5. 5. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63, 618-624.
6. 6. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11, 167-180.
7. 7. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990, 21, 1164-1167.
8. 8. Ramachandra S, Machin L, Ashley S, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in situ breast carcinoma -a detailed morphological analysis. J Pathol 1990, 161, 7-14.
9. 9. De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virch Arch 1995, 426, 107-115.
10. 10. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ. Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993, 24, 463-468.
11. 11. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL. p53 Mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994, 71, 67-72.
12. 12. van Agthoven T, Timmermans M, Foekens JA, Dorssers LCJ, Henzen-Logmans SC. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 1994, 144, 1238-1246.
13. 13. Chaudhuri B, Crist KA, Mucci S, Malafa M, Chaudhuri PK. Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 1993, 113, 134-137.
14. 14. Poller DN, Snead DRJ, Roberts EC, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 1993, 68, 156-161.
15. 15. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994, 11, 208-214.
16. 16. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994, 11, 199-207.
17. 17. Solin LJ, Yeh I-T, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Cancer 1993, 71, 2532-2542.
18. 18. Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981, 75, 734-738.
19. 19. Craig Allred D, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992, 23, 974-979.
20. 20. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford, Blackwell Scientific, 1987.
21. 21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
22. 22. Mantel N. Evaluation of survival data and two new rank order statistic arising in its consideration. Cancer Chemother Rep 1966, 50, 163-170.
23. 23. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987, 235, 177-182.
24. 24. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. Am J Surg Pathol 1992, 16, 1183-1196.
25. 25. Poller DN, Hutchings CE, Galea M, et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 1992, 66, 583-588.
26. 26. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992, 69, 1174-1181.
27. 27. Soomro S, Shousha S, Sinnet HD, et al. Oestrogen and progesterone receptors in screen-detected breast carcinoma: an immunohistological study using paraffin sections. Histopathology 1992, 21, 543-547.
28. 28. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993, 23, 239-248.
29. 29. Gion M, Mione R, Dittadi R, et al. Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 1995, 31, 671-677.
30. 30. Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993, 143, 867-874.
31. 31. Gasparini G, Barbareschi M, Boracchi P, et al. 67-kDA Laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node negative breast cancer. Int J Cancer 1995, 60, 604-610.
32. 32. White J, Gustafson G, Levine A, et al. Outcome and prognostic factors for local recurrence in mammographically detected ductal carcinoma in situ of the breast treated with conservative surgery and radiation therapy (Abstract). Int J Radiat Oncol Biol Phys 1993, 27 (Suppl.), 31.